US FDA Targets Expanding Conduit For Supplement GMP Compliance Information
Executive Summary
Gathering GMP information can be as problematic for agency as keeping tabs on all supplements available to US consumers. “Just to be clear, FDA believes we have a data gap in understanding the extent of the dietary supplements in the marketplace,” says ODSP Director Cara Welch.
You may also be interested in...
US FDA Touts Benefits From Remote Assessments, Manufacturers Feel Burden – Trade Groups
CHPA members’ feedback on RRAs indicate that “time and resources saved by FDA do not translate to time saved by the manufacturer.” CRN suggests FDA “clearly identify the purpose of the RRA in its initial request and limit requested documents to only those directly related to the purpose of the RRA.”
Durbin Lights Supplement MPL Flare In US Senate
Senate votes down Illinois Democrat’s proposal to amend stopgap appropriations bill with language calling for establishing mandatory products listing program in FDA. But proposal to give FDA MPL authority likely will return in Congress, says Natural Products Association.
Keep Big Picture In Focus, Have Clarity On Specifics Responding To GMP Violations
Avoid “absolute chaos” and last-minute changes as well as over-reaction responding to FDA officials’ form 483s listing GMP violations found during inspections, says Teresa Gorecki, practice director at Compliance Architects.